Abstract
Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.
Keywords: Angiogenesis, VEGF, Combination Therapy, Biomarker, Resistance, Toxicity, bevacizumab, Avastin, TKRI, sunitinib, GIST, pazopanib, EGFR, PDGFR, FGFR, CRC, NSCLC, ABT-869, Axitinib, BIBF1120, Brivanib, Cediranib, Dovitinib, Foretinib, Motesanib, Sorafenib, Vandetanib, Vatalanib, ZD6474, carboplatin, paclitaxel, trastuzumab, Radio-Immunotherapy, Tregs, TKRI therapy, PlGF, hypothyroidism, neuropathy
Current Pharmaceutical Design
Title: Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Volume: 16 Issue: 35
Author(s): Michele Moschetta, Marta Cesca, Francesca Pretto and Raffaella Giavazzi
Affiliation:
Keywords: Angiogenesis, VEGF, Combination Therapy, Biomarker, Resistance, Toxicity, bevacizumab, Avastin, TKRI, sunitinib, GIST, pazopanib, EGFR, PDGFR, FGFR, CRC, NSCLC, ABT-869, Axitinib, BIBF1120, Brivanib, Cediranib, Dovitinib, Foretinib, Motesanib, Sorafenib, Vandetanib, Vatalanib, ZD6474, carboplatin, paclitaxel, trastuzumab, Radio-Immunotherapy, Tregs, TKRI therapy, PlGF, hypothyroidism, neuropathy
Abstract: Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.
Export Options
About this article
Cite this article as:
Moschetta Michele, Cesca Marta, Pretto Francesca and Giavazzi Raffaella, Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455021
DOI https://dx.doi.org/10.2174/138161210794455021 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Bioenergetics of Isolated Mitochondria from Different Animal Models for Diabetes
Current Diabetes Reviews Current Concepts on Prenatal Diagnosis and Management of Fetal Tachyarrythmias
Current Cardiology Reviews Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Mitochondria, Cellular Stress Resistance, Somatic Cell Depletion and Lifespan
Current Aging Science Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems
Current Pharmaceutical Design Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Endothelin-1 and Endothelin Converting Enzyme-1 in Human Atherosclerosis - Novel Targets for Pharmacotherapy in Atherosclerosis
Current Vascular Pharmacology Evaluation of the Pulmonary Veins and Left Atrial Volume using Multidetector Computed Tomography in Patients Undergoing Catheter Ablation for Atrial Fibrillation
Current Cardiology Reviews Endocrine Therapies and QTc Prolongation
Current Drug Safety Antidiabetic Potential of Naturally Occurring Sesquiterpenes: A Review
Current Topics in Medicinal Chemistry Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle
Current Genomics Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Sildenafil and Cardioprotection
Current Pharmaceutical Design Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Synergy of microRNA and Stem Cell: A Novel Therapeutic Approach for Diabetes Mellitus and Cardiovascular Diseases
Current Diabetes Reviews